fbpx

A Novel Antifibrinolytic Agent

Using a new mechanism of action to inhibit fibrinolysis, our patented preclinical candidate addresses unmet medical needs (e.g. IntraCranial Hemorrhage where no treatment is currently available).

CM-352

Our optimized lead compound, CM-352, is highly efficient in preclinical models at main bleeding scenarios (e.g. major surgery and trauma) and is safe (no thrombus formation, no impact on global hemostasis, no alteration on anatomopathological analysis, no cardiovascular safety risks, no Acute Toxicity and no off-target effects).

TAIL BLEEDING

The minimal effective dose (10 μg/kg) of CM-352 reduces bleeding time by 89% and blood loss by 61% in mice.

TAIL BLEEDING

The minimal effective dose (10 μg/kg) of CM-352 reduces bleeding time by 89% and blood loss by 61% in mice.

SEVERE MODEL

In a severe bleeding scenario (murine hepatectomy), only CM-352 significantly reduced blood loss whereas TXA and Aprotinin are ineffective.

ICH MODEL

Both early and late treatment with CM-352 after IntraCranial Hemorrhage (ICH) onset successfully reduced Hematoma expansion and improved functional and neurological impairments.

ICH MODEL

Both early and late treatment with CM-352 after IntraCranial Hemorrhage (ICH) onset successfully reduced Hematoma expansion and improved functional and neurological impairments.

ANEURYSM

An increased survival rate in animals with aneurysms is observed in CM-352 treated mice when compared to controls, as well as a decrease in the number of aneurysms and reduced ICH volume.

Want To Start Investing With Us?

Investing in the novel biopharmaceutical technology of Hemostatics can help accelerating the development of innovative solutions addressing potentially life-threatening hemorrhagic conditions.